197 related articles for article (PubMed ID: 25140386)
21. Effects of intrapleural heparin or urokinase on the extent of tetracycline-induced pleural disease.
Strange C; Baumann MH; Sahn SA; Idell S
Am J Respir Crit Care Med; 1995 Feb; 151(2 Pt 1):508-15. PubMed ID: 7842213
[TBL] [Abstract][Full Text] [Related]
22. Gene expression of fibrinolytic factors urokinase plasminogen activator and plasminogen activator inhibitor-1 in rabbit temporo-mandibular joint cartilage with disc displacement.
Zhan J; Gu ZY; Wu LQ; Zhang YK; Hu JA
Chin Med J (Engl); 2005 Jun; 118(12):1000-6. PubMed ID: 15978208
[TBL] [Abstract][Full Text] [Related]
23. Retrospective review comparing intrapleural fibrinolytic therapy (alteplase) and surgical intervention in complex pleural effusion.
Abdul Hamid MF; Hasbullah AHH; Mohamad Jailaini MF; Nik Abeed NN; Ng BH; Haron H; Md Ali NA; Ismail MI; Nik Ismail NA; Abdul Rahman MR; Ban AY
BMC Pulm Med; 2022 Nov; 22(1):439. PubMed ID: 36419155
[TBL] [Abstract][Full Text] [Related]
24. Lack of durable protection against cotton smoke-induced acute lung injury in sheep by nebulized single chain urokinase plasminogen activator or tissue plasminogen activator.
Fukuda S; Enkhbaatar P; Nelson C; Cox RA; Wolfson MR; Shaffer TH; Williams RO; Surasarang SH; Sawittree S; Florova G; Komissarov AA; Koenig K; Sarva K; Ndetan HT; Singh KP; Idell S
Clin Transl Med; 2018 Jun; 7(1):17. PubMed ID: 29916009
[TBL] [Abstract][Full Text] [Related]
25. Single-chain urokinase alone or complexed to its receptor in tetracycline-induced pleuritis in rabbits.
Idell S; Mazar A; Cines D; Kuo A; Parry G; Gawlak S; Juarez J; Koenig K; Azghani A; Hadden W; McLarty J; Miller E
Am J Respir Crit Care Med; 2002 Oct; 166(7):920-6. PubMed ID: 12359647
[TBL] [Abstract][Full Text] [Related]
26. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets.
Wang X; Palasubramaniam J; Gkanatsas Y; Hohmann JD; Westein E; Kanojia R; Alt K; Huang D; Jia F; Ahrens I; Medcalf RL; Peter K; Hagemeyer CE
Circ Res; 2014 Mar; 114(7):1083-93. PubMed ID: 24508759
[TBL] [Abstract][Full Text] [Related]
27. A long-acting PAI-1 inhibitor reduces thrombus formation.
Peng S; Xue G; Gong L; Fang C; Chen J; Yuan C; Chen Z; Yao L; Furie B; Huang M
Thromb Haemost; 2017 Jun; 117(7):1338-1347. PubMed ID: 28405670
[TBL] [Abstract][Full Text] [Related]
28. Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide.
Zhang L; Strickland DK; Cines DB; Higazi AA
J Biol Chem; 1997 Oct; 272(43):27053-7. PubMed ID: 9341144
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of PAI-1: a new anti-thrombotic approach.
Wu Q; Zhao Z
Curr Drug Targets Cardiovasc Haematol Disord; 2002 Jun; 2(1):27-42. PubMed ID: 12769655
[TBL] [Abstract][Full Text] [Related]
30. Intrapleural activation, processing, efficacy, and duration of protection of single-chain urokinase in evolving tetracycline-induced pleural injury in rabbits.
Idell S; Allen T; Chen S; Koenig K; Mazar A; Azghani A
Am J Physiol Lung Cell Mol Physiol; 2007 Jan; 292(1):L25-32. PubMed ID: 16980376
[TBL] [Abstract][Full Text] [Related]
31. A recombinant antibody-targeted plasminogen activator with high affinity for activated platelets increases thrombolytic potency in vitro and in vivo.
Wan H; Liu Z; Xia X; Gu J; Wang B; Liu X; Zhu M; Li P; Ruan C
Thromb Res; 2000 Feb; 97(3):133-41. PubMed ID: 10680644
[TBL] [Abstract][Full Text] [Related]
32. Effects of thrombin on steroid-modulated cultured endometrial stromal cell fibrinolytic potential.
Lockwood CJ; Krikun G; Aigner S; Schatz F
J Clin Endocrinol Metab; 1996 Jan; 81(1):107-12. PubMed ID: 8550736
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in early and late gestational mouse skin and skin wounds.
Huang EY; Wu H; Island ER; Chong SS; Warburton D; Anderson KD; Tuan TL
Wound Repair Regen; 2002; 10(6):387-96. PubMed ID: 12453143
[TBL] [Abstract][Full Text] [Related]
34. Use of intrapleural tissue plasminogen activator and deoxyribonuclease in pleural space infections: an update on alternative regimens.
Gilbert CR; Gorden JA
Curr Opin Pulm Med; 2017 Jul; 23(4):371-375. PubMed ID: 28399008
[TBL] [Abstract][Full Text] [Related]
35. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1.
Higazi AA; Mazar A; Wang J; Reilly R; Henkin J; Kniss D; Cines D
Blood; 1996 May; 87(9):3545-9. PubMed ID: 8611676
[TBL] [Abstract][Full Text] [Related]
36. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
Debrock S; Declerck PJ
Biochim Biophys Acta; 1997 Feb; 1337(2):257-66. PubMed ID: 9048903
[TBL] [Abstract][Full Text] [Related]
37. Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme.
Petersen HH; Hansen M; Schousboe SL; Andreasen PA
Eur J Biochem; 2001 Aug; 268(16):4430-9. PubMed ID: 11502203
[TBL] [Abstract][Full Text] [Related]
38. The fibrinolytic system: A new target for treatment of depression with psychedelics.
Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
[TBL] [Abstract][Full Text] [Related]
39. Update on Novel Targeted Therapy for Pleural Organization and Fibrosis.
Tucker TA; Idell S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163509
[TBL] [Abstract][Full Text] [Related]
40. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Wang Q; Shaltiel S
BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
